VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec. 11, 2013) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to 'reboot' the body's immune system to treat cancer and autoimmune disease, announced it has appointed Rashieda Gluck as Vice President, Clinical Operations.

As Vice President, Clinical Operations, Rashieda Gluck will lead development, execution and delivery of Qu Biologics' clinical trial programs.

Qu Biologics Chief Executive Officer Dr. Hal Gunn commented, "We are at an important stage of our growth with one clinical trial in Crohn's disease ongoing and other trials in cancer being planned. Rashieda's more than 20 years of clinical operations experience will be valuable to the development of our clinical programs as we further investigate the potential treatment benefits of our site specific immunomodulators. We are very pleased to welcome her to the leadership team."

About Rashieda Gluck

Rashieda Gluck is a clinical trial development and operational execution specialist with more than 20 years of experience spanning all phases of clinical development. She has proven success in strategic planning and delivery of high quality clinical programs and extensive experience in building and overseeing high performing, cross functional teams. In her most recent position as VP, Head of Global Clinical Operations at Vifor Pharma, based in Zurich Switzerland, she built and led the clinical operations department and held overall accountability for the execution and delivery of all global clinical trials across all development compounds. Rashieda has served in increasingly senior positions at major pharmaceutical companies including Chiron, GSK, and Novartis and has built and contributed to the clinical success of start-up companies such as Aspreva Pharmaceuticals.

About Qu Biologics

Qu Biologics develops Site Specific Immunomodulators (SSI), a novel class of immunotherapies that aim to reboot the body's immune system. SSIs are designed to stimulate an immune response in targeted organs or tissues to potentially reverse the chronic inflammation underlying many conditions including cancer and autoimmune disease. The company recently launched a Phase 1/2 clinical trial to research SSI therapy for the treatment of Crohn's disease.

Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body's immune response to chronic disease; and Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control in Canada and internationally. For more information, visit and

Contact Information:

Qu Biologics Inc.
Julie Jang
Director, Communications
604.734.1450 ext. 41491